Recent studies suggest that differences in lymphocyte counts may serve as a potential predictor of COVID-19 disease severity (Tan et al., 2020).
Epimune's i.Mune™ TBNK (RUO) test allows lymphocyte enumeration from a drop of dried blood allowing self sampling at home via finger-prick. This could help to identify COVID-19 patients at risk for severe disease progression and to initiate early and targeted implementation of protective measures.
Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system
Using epigenetics, Epimune develops & commercializes molecular diagnostic tests for immune cell quantification from a drop of blood